Abstract: Mapping a message sent between computing applications to a computing environment associated with one of the computing applications. The computing environment can be a test environment used for developing the computing application. Identification of the computing environment and other data from the message can be extracted from a header of the message and logged. The logged data can be stored in a storage and displayed via a user interface.

Abstract: Mapping a message sent between computing applications to a computing environment associated with one of the computing applications. The computing environment can be a test environment used for developing the computing application. Identification of the computing environment and other data from the message can be extracted from a header of the message and logged. The logged data can be stored in a storage and displayed via a user interface.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: Mapping a message sent between computing applications to a computing environment associated with one of the computing applications. The computing environment can be a test environment used for developing the computing application. Identification of the computing environment and other data from the message can be extracted from a header of the message and logged. The logged data can be stored in a storage and displayed via a user interface.

Abstract: The present invention relates to a composition comprising an interferon alpha (IFN-?) subtype which is a hybrid of IFN-?10 and IFN-?14 for use in the prevention or treatment of a viral infection, as well as a method of treatment and/or prophylaxis of a viral infection using said IFN-? hybrid.

Abstract: The present invention relates to compositions and methods for preventing or treating canine pruritic disease, optionally wherein the canine pruritic disease is canine atopic dermatitis (AD) in general, and a synthetic canine interferon (IFN)-alpha (?) for use in said treatment or prophylaxis in particular, as well as a composition and method comprising the same and a method of production of the synthetic canine interferon-alpha.

Abstract: The present invention relates to the field of assay devices and methods for performing assays, such as immunoassays. The system comprises a means to receive the target sample collected from a subject; a means to measure the target analyte possibly present in said target sample; and a process of measuring the target analytes in real time manner. The target analyte includes but is not limited to any biological analyte, microbial entity like those of viral or bacterial sources such as SARS-CoV-2. The invention thus primarily relates to measuring analytes of interest to detect and treat related indications, such as COVID-19.

Abstract: Compositions and methods for preventing or treating a coronavirus infection and viral infections more generally are provided. In particular, compositions for preventing or treating infection from Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1), Human Coronavirus NL63, Human Coronavirus HKU1, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2 or Covid19) are provided.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: There is provided a method and compositions for the treatment and/or prophylaxis of psoriasis or atopic dermatitis, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of an interferon alpha subtype, wherein the interferon 3 alpha subtype is IFN-?14, HYBRID 1 or a combination of IFN-?14 and HYBRID 1.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role, such as inflammatory responses and autoimmune diseases. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: A compressible adjunct is used with a surgical instrument. The compressible adjunct includes a hollow fibrous construct and a core fibrous construct housed within the hollow fibrous construct, wherein the hollow fibrous construct comprises at least one biocompatible material that has experienced at least one transition from a more ordered phase to a less ordered phase in response to heating the hollow fibrous construct to a predetermined temperature.

Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.

Abstract: A method is provided for the treatment and/or prophylaxis of a condition where an enhancement of a Th1-mediated immune response and suppression of a Th2/Th17-mediated immune response are desired. The method comprises the step of administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from IFN-?10, IFN-?14, and a hybrid thereof. The condition to be treated may be selected from the group consisting of an autoimmune disease, an inflammatory disease (e.g. inflammatory bowel disease) and allergy or an associated allergic condition.

Abstract: A composition for treating waters, e.g. ballast water or injection water for oil recovery, to kill in-situ aquatic invasive species comprises at least one biocide capable of killing both animal and plant micro-organisms. The at least one biocide preferably comprises Brilliant Green, Gentian Violet, and/or erythrosine, and a wetting agent or detergent-like compound such as CTAB or CTAC. The invention also relates to a system for treating ballast water in situ comprising means for injecting a composition for treating ballast water; means for measuring the flow rate or amount of ballast water to be treated; means for controlling the dosing of the composition; and means for storing or receiving the composition. The invention also relates to a method of detecting viable aquatic organisms in ballast water in situ comprising detecting metabolism in viable micro-organisms in ballast water and, therefore, measuring the efficacy of any treatment.

Abstract: Disclosed is a system and method for automating the performance of a conjugate or sandwich assay, and a cassette for use with the system. The cassette comprises a fluid conduit and one or more chambers in the fluid conduit, from which a measurement may be acquired from a sample using a cassette reader device. Sample and reagent fluids may be caused to flow along the fluid conduit to perform the assay and control over the progress of the assay may be exerted at least in part by the arrangement of chambers in the fluid conduit. Also disclosed is a tablet or bead for use with the assay system, which may be incorporated in the cassette. The tablet or bead may comprise one or more reagents to be used in the assay, in a soluble matrix. Use of an acridan or acridinium ester label may enable a sensitive measurement to be rapidly acquired. The assay may be configured to be performed by a clinician at the point of use or care.

Abstract: A method is provided for the treatment and/or prophylaxis of a condition where an enhancement of a Th1-mediated immune response and suppression of a Th2/Th17-mediated immune response are desired. The method comprises the step of administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from IFN-?10, IFN-?14, and a hybrid thereof. The condition to be treated may be selected from the group consisting of an autoimmune disease, an inflammatory disease (e.g. inflammatory bowel disease) and allergy or an associated allergic condition.

Abstract: A composition for treating waters, e.g. ballast water or injection water for oil recovery, to kill in-situ aquatic invasive species comprises at least one biocide capable of killing both animal and plant micro-organisms. The at least one biocide preferably comprises Brilliant Green, Gentian Violet, and/or erythrosine, and a wetting agent or detergent-like compound such as CTAB or CTAC. The invention also relates to a system for treating ballast water in situ comprising means for injecting a composition for treating ballast water; means for measuring the flow rate or amount of ballast water to be treated; means for controlling the dosing of the composition; and means for storing or receiving the composition. The invention also relates to a method of detecting viable aquatic organisms in ballast water in situ comprising detecting metabolism in viable micro-organisms in ballast water and, therefore, measuring the efficacy of any treatment.